awmsg logo



pazopanib (Votrient®)


Reference No. 549

Publication date:
03/12/2013


Last review date:
01/12/2016

Appraisal information

pazopanib (Votrient®) 200 mg film-coated tablet
pazopanib (Votrient®) 400 mg film-coated tablet


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 20/02/2013
AWMSG meeting date: 16/10/2013
   
   
Submission Type: Independent Review
Status: Recommended
Advice No: 2513
Ministerial ratification: 02/12/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Pazopanib (Votrient®) is recommended as an option for use within NHS Wales for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download